Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Effect of utilization policies for fluoroquinolones: a pilot study in nova scotia hospitals.

Kent AJ, Sketris IS, Johnston BL, Sommers RB.

Can J Hosp Pharm. 2009 Jan;62(1):12-20.

2.

Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies.

Sketris IS, Metge C, Shevchuk Y, Comeau DG, Kephart GC, Blackburn J, MacCara M, Laturnas A.

Am J Geriatr Pharmacother. 2004 Mar;2(1):24-35.

PMID:
15555476
3.
4.

Fluoroquinolone resistance during 2000-2005: an observational study.

Ryan RJ, Lindsell C, Sheehan P.

BMC Infect Dis. 2008 May 24;8:71. doi: 10.1186/1471-2334-8-71.

5.

Fluoroquinolone utilization among inpatients in a teaching hospital in western Nepal.

Shankar PR, Upadhyay DK, Mishra P, Subish P, Dubey AK, Saha AC.

J Pak Med Assoc. 2007 Feb;57(2):78-82.

6.

Antibiotic use in non-university regional acute care general hospitals in southwestern Germany, 2001-2002.

Kern WV, de With K, Steib-Bauert M, Fellhauer M, Plangger A, Probst W; MABUSE-INTERREGIO-II Project Team.

Infection. 2005 Oct;33(5-6):333-9.

PMID:
16258863
7.

Impact of a limited fluoroquinolone reimbursement policy on antimicrobial prescription claims.

MacCara ME, Sketris IS, Comeau DG, Weerasinghe SD.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):852-8.

PMID:
11485132
8.

Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting.

Kuster SP, Ruef C, Ledergerber B, Hintermann A, Deplazes C, Neuber L, Weber R.

Infection. 2008 Dec;36(6):549-59. doi: 10.1007/s15010-008-7462-z. Epub 2008 Nov 13. Review.

PMID:
19011740
9.

[Recent antibiotic use in German acute care hospitals - from benchmarking to improved prescribing and quality care].

Kern WV, Fellhauer M, Hug M, Hoppe-Tichy T, Först G, Steib-Bauert M, de With K.

Dtsch Med Wochenschr. 2015 Nov;140(23):e237-46. doi: 10.1055/s-0041-105938. Epub 2015 Nov 19. German.

10.

Increase and change in pattern of hospital antimicrobial use, Denmark, 1997-2001.

Müller-Pebody B, Muscat M, Pelle B, Klein BM, Brandt CT, Monnet DL.

J Antimicrob Chemother. 2004 Dec;54(6):1122-6. Epub 2004 Nov 10.

PMID:
15537692
11.

Implementation of an intensified antibiotic stewardship programme targeting third-generation cephalosporin and fluoroquinolone use in an emergency medicine department.

Borde JP, Kern WV, Hug M, Steib-Bauert M, de With K, Busch HJ, Kaier K.

Emerg Med J. 2015 Jul;32(7):509-15. doi: 10.1136/emermed-2014-204067. Epub 2014 Sep 26.

PMID:
25261006
12.

Analysis of antimicrobial consumption and cost in a teaching hospital.

Bozkurt F, Kaya S, Tekin R, Gulsun S, Deveci O, Dayan S, Hoşoglu S.

J Infect Public Health. 2014 Mar-Apr;7(2):161-9. doi: 10.1016/j.jiph.2013.09.007. Epub 2013 Nov 26.

13.

Impact of hospital formularies on fluoroquinolone prescribing in emergency departments.

Aspinall SL, Metlay JP, Maselli JH, Gonzales R.

Am J Manag Care. 2007 May;13(5):241-8.

14.

Feasibility and impact of an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center.

Borde JP, Kaier K, Steib-Bauert M, Vach W, Geibel-Zehender A, Busch H, Bertz H, Hug M, de With K, Kern WV.

BMC Infect Dis. 2014 Apr 15;14:201. doi: 10.1186/1471-2334-14-201.

15.

Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility.

Rifenburg RP, Paladino JA, Bhavnani SM, Haese DD, Schentag JJ.

Am J Health Syst Pharm. 1999 Nov 1;56(21):2217-23.

PMID:
10565701
16.

Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital.

Muller A, Monnet DL, Talon D, Hénon T, Bertrand X.

Br J Clin Pharmacol. 2006 May;61(5):585-91.

17.

A comparison of antidepressant use in Nova Scotia, Canada and Australia.

Smith AJ, Sketris I, Cooke C, Gardner D, Kisely S, Tett SE.

Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):697-706. doi: 10.1002/pds.1541.

PMID:
18181227
18.

Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.

Urbánek K, Kolár M, Strojil J, Koukalová D, Cekanová L, Hejnar P.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):741-5.

PMID:
15880441
19.

A 3 year survey on the use of antibacterial agents in five Italian hospitals.

Vaccheri A, Silvani MC, Bersaglia L, Motola D, Strahinja P, Vargiu A, Poluzzi E, Montanaro N.

J Antimicrob Chemother. 2008 Apr;61(4):953-8. doi: 10.1093/jac/dkn010. Epub 2008 Jan 24.

PMID:
18218639
20.

Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.

Walbrown MA, Aspinall SL, Bayliss NK, Stone RA, Cunningham F, Squier CL, Good CB.

J Manag Care Pharm. 2008 Jan-Feb;14(1):34-40.

Supplemental Content

Support Center